A founder’s guide to Canada’s refundable SR&ED credit and the newly supercharged US R&D tax credit — and how to pick the right side of the border before you incorporate.

SR&ED vs R&D Tax Credit isn’t an academic tax question — it’s a cash-flow decision that can add or subtract hundreds of thousands of dollars from your runway before you ever raise another round. Most founders pick their incorporation jurisdiction based on where their lawyer is, where their lead investor sits, or which Twitter thread they read at 1 a.m. Almost none of them run the numbers on Canada’s Scientific Research and Experimental Development (SR&ED) program against the US federal research credit before signing incorporation papers. That’s a mistake, because in 2026 the gap between these two programs is wider — and in some ways narrower — than it’s ever been.

Canada just passed the biggest SR&ED expansion in a decade. The US just reversed one of the most punishing tax changes of the last twenty years. Both events happened within months of each other, and almost nobody has explained what they mean side by side for a founder actually choosing between a CCPC and a Delaware C-corp. That’s what this guide does.

What Is SR&ED, Exactly?

SR&ED is Canada’s flagship innovation incentive, administered by the Canada Revenue Agency, and it works differently from almost every other R&D incentive in the world for one reason: it can pay you in cash even if you’ve never turned a profit. If you’re a Canadian-controlled private corporation (CCPC) doing eligible research — building new software architecture, solving a technical uncertainty, running systematic experimentation — you can claim a refundable investment tax credit against your qualified expenditures, whether or not you owe a dollar of income tax.

As of March 2026, this program got dramatically more generous. Bill C-15, the Budget 2025 Implementation Act, received Royal Assent and enacted the changes that had been stuck in legislative limbo since the 2024 Fall Economic Statement. The enhanced-rate expenditure limit was raised from $3 million to $6 million, which raises the maximum annual refundable credit from $1.05 million to $2.1 million for qualifying corporations. The enhanced rate itself sits at 35% and is fully refundable; spending above that limit, or claims from corporations that don’t qualify for the enhanced rate, still earn a 15% credit that’s generally non-refundable. Capital property acquired after December 15, 2024 is once again eligible for SR&ED investment tax credits, reversing a 2014 policy that had excluded equipment and machinery from the program for over a decade. The phase-out thresholds for the enhanced rate were also widened, from $10 million–$50 million to $15 million–$75 million in prior-year taxable capital, which means more mid-sized companies keep access to the 35% rate for longer as they scale. The State of SR&ED 2026: Canada’s R&D Tax Credit by the Numbers

The administrative side got faster too. Starting April 1, 2026, companies can opt into a pre-claim approval process that targets a 90-day review instead of the previous 180 days, alongside increased use of AI in program administration. For a founder used to SR&ED claims taking most of a year to process, that’s a real change to when cash actually lands.

If you want the primary source, the Canada Revenue Agency’s SR&ED program page has the current eligibility criteria and filing forms.

What Is the US R&D Tax Credit (Section 41)?

The US equivalent lives in Internal Revenue Code Section 41 and works on a fundamentally different mechanism: it’s a credit against tax you owe, not a cash refund on spending you incurred. Companies calculate qualified research expenses (QREs) — wages, supplies, and a portion of contract research tied to activities that pass the IRS’s four-part test — and then choose between the regular credit (roughly 20% of QREs above a historical base amount) or the Alternative Simplified Credit, which runs 14% of QREs above 50% of the average of the prior three years’ QREs, or 6% for companies with no R&D history to compare against.

The catch that trips up almost every early-stage founder: this credit is non-refundable against income tax by default. If you’re pre-revenue or pre-profit, a credit against tax you don’t owe is worth zero dollars today — you carry it forward, sometimes for years, until you’re finally profitable enough to use it.

There is one major exception, and it’s the one every US-incorporated startup should know cold. Under Section 41(h), a qualified small business — defined as having gross receipts under $5 million in the credit year and no gross receipts from more than five years before that year — can apply the research credit directly against payroll taxes instead of income tax. Since 2023, the Inflation Reduction Act raised that annual payroll offset ceiling from $250,000 to $500,000, applied first against the employer’s 6.2% Social Security portion and then against the 1.45% Medicare portion. That’s real, current-year cash for a startup burning payroll and doing nothing else — no profitability required.

For the technical framework, the IRS’s Form 6765 instructions walk through both credit calculation methods.

SR&ED vs R&D Tax Credit: The Side-by-Side Comparison

Here’s where the SR&ED vs R&D Tax Credit comparison gets concrete. Strip away the jargon and these are the differences that actually move your bank balance:

	Canada — SR&ED	US — Section 41 / 174A
Refundable to pre-profit companies?	Yes, up to 35% for qualifying CCPCs	Only via QSB payroll offset, capped at $500K/year
Enhanced rate & limit	35% on up to $6M in qualified spend	14–20% depending on method, no hard dollar cap
Who qualifies for the top rate	Canadian-controlled private corporations (and now eligible public corporations)	Any US taxpayer; payroll offset restricted to QSBs
Cost of doing R&D deducted immediately?	Yes, current expenditures always deductible	Yes since 2025 (domestic R&E only, via new Section 174A)
Foreign R&D treatment	Up to 10% of Canadian SR&ED wages can cover work done abroad	Foreign R&E still amortized over 15 years, not immediately deductible
Filing deadline	18 months after fiscal year-end	Filed with annual return; amendments generally open 3 years
Carryforward if unused	Non-refundable portion carries forward 20 years, back 3	Unused credit carries forward 20 years

The single biggest line in that table is refundability. A Canadian CCPC spending $1 million on eligible R&D with no revenue yet can genuinely expect a cheque from the CRA. A US startup in the same position gets, at best, $500,000 in payroll tax relief if it qualifies as a QSB — and nothing at all if it’s already grown past the $5 million gross receipts threshold or has been generating revenue for more than five years.

The OBBBA Earthquake: Why the US Suddenly Got Competitive

For three brutal years — 2022 through 2024 — the US side of this comparison was actively hostile to R&D-heavy companies. The Tax Cuts and Jobs Act had quietly required businesses to capitalize and amortize research expenditures instead of deducting them immediately, turning a same-year tax deduction into a multi-year drip. Startups that had always written off engineering salaries in the year they were paid suddenly had to spread that deduction over five years domestically, fifteen years for anything done offshore. It inflated taxable income for companies that weren’t actually more profitable, and it caught a lot of founders completely off guard.

That changed in July 2025. The One Big Beautiful Bill Act (OBBBA) enacted new Internal Revenue Code Section 174A, restoring immediate expensing for domestic research and experimental costs for tax years beginning after December 31, 2024, and the change is permanent, with no sunset. Foreign R&E remains stuck on the 15-year amortization schedule, so where your engineers sit still matters enormously — but domestic US research costs are, once again, fully deductible in the year you spend the money.

Small businesses under $31 million in average gross receipts were given a window to amend 2022–2024 returns and retroactively apply the new expensing rules — that window closed July 6, 2026. If you’re reading this after that date and never filed, that specific retroactive door is shut, though standard amended-return rules may still apply depending on your filing history. Larger companies that missed the retroactive election can still recover whatever domestic R&E they had capitalized in 2022–2024, spread across 2025 and 2026. Strike Tax Advisory

The practical upshot: the US closed a real competitive gap with Canada on the deduction side. It did not close the gap on the refund side. That distinction is the whole ballgame for a pre-revenue startup.

Refundable vs Non-Refundable: The Difference That Actually Matters at 2 A.M.

Founders overweight the headline percentage — 35% sounds better than 20%, so SR&ED must be better, right? Wrong question. The number that matters isn’t the rate, it’s whether the credit shows up as cash when you actually need it.

A non-refundable credit is an IOU against future profit. If your startup is eighteen months from any kind of profitability — which describes most venture-backed companies — a non-refundable credit sits on your balance sheet as a deferred asset, not a wire transfer. It’s genuinely valuable eventually. It does nothing for your Wednesday payroll run.

SR&ED’s refundability is what makes it functionally different from almost every comparable program in the OECD. A CCPC can file its claim, get audited or fast-tracked under the new 90-day process, and receive an actual cash refund regardless of taxable income. That’s why Canadian SR&ED consultants routinely describe it as “non-dilutive funding” in the same breath as a grant, not just a tax break — because from a cash-flow perspective, that’s exactly what it behaves like.

The US payroll offset gets you part of the way there, but it’s capped, it’s restricted to companies under $5 million in gross receipts and under five years of revenue history, and once you outgrow either threshold, you’re back to a non-refundable credit sitting in carryforward until you’re profitable.

Where Should Founders Incorporate? A Stage-by-Stage Framework

There’s no universal answer to SR&ED vs R&D Tax Credit — the right call depends almost entirely on your stage, your funding source, and where your engineers physically sit.

Pre-seed and bootstrapped

If you’re self-funded or angel-funded, pre-revenue, and your technical team is in Canada, staying as a CCPC and claiming SR&ED is usually the clear winner. The refundable cash is often the difference between hiring your next engineer and not. There’s no US equivalent that pays cash this early without revenue.

Seed to Series A, US-bound

If you’re planning to raise a US-led round, the picture gets more complicated. US investors frequently require or strongly prefer a Delaware C-corp — which raises the structural issue covered in the next section. If your engineering team is US-based, the restored Section 174A expensing plus the QSB payroll offset gives you real, current cash flow benefit even before profitability, just with a lower ceiling than SR&ED.

Growth stage, post-Series A

Once you’re past $5 million in gross receipts or five years of revenue, the US payroll offset disappears and you’re carrying a non-refundable credit forward. At this stage the US credit becomes a straightforward tax-planning tool rather than a cash-flow lifeline, and the incorporation decision should be driven by where your customers, investors, and talent actually are — not by chasing the R&D credit specifically.

A hybrid structure — Canadian operating subsidiary doing the engineering, US or Delaware parent handling sales and fundraising — lets many companies access pieces of both systems, but it introduces the next problem.

The Delaware Flip Problem: How US VC Money Can Kill Your SR&ED Refund

This is the trap that catches Canadian founders most often, and almost nobody explains it clearly before term sheets get signed.

To claim the enhanced 35% refundable SR&ED rate, a company generally must qualify as a Canadian-controlled private corporation — meaning, broadly, that it isn’t controlled by non-residents or by a public corporation. When a Canadian startup does the classic “Delaware flip” to satisfy a US lead investor — creating a Delaware Newco that acquires the Canadian operating company as a subsidiary — control of that Canadian entity typically shifts to the new US parent. The moment non-residents control the Canadian sub, it generally stops being a CCPC.

The Canadian subsidiary can usually still claim SR&ED on the research it performs. What it loses is the enhanced refundable rate. It drops to the basic 15% credit, and — critically — that 15% is typically non-refundable for a non-CCPC. So a founder who flips to Delaware for a US round can watch their SR&ED refund evaporate in the same transaction that brought in the capital, right when they might assume they’re flush and don’t need it — except many flips happen well before the round closes and the cash lands.

This isn’t a reason to avoid US capital. It’s a reason to model the SR&ED impact into the term sheet negotiation and the timing of the flip, ideally with a cross-border tax advisor who has actually structured this before, not after the closing dinner.

Claiming Both: How Cross-Border R&D Teams Avoid Double-Dipping

Plenty of real companies have engineers on both sides of the border, and the good news is you generally don’t have to pick one program exclusively — you have to be precise about which dollars go where.

SR&ED lets a Canadian claimant include certain wages for SR&ED work carried out outside Canada, capped at 10% of the salaries and wages directly attributable to SR&ED performed inside Canada. So a small amount of cross-border engineering cost can still flow into a Canadian claim. On the US side, Section 41 generally requires the qualified research to be conducted within the United States to count as a qualified research expense at all — Canadian-based engineering work doesn’t generate US QREs, full stop. PwC Canada

The practical rule cross-border teams follow: track R&D costs by entity and by the country where the work was physically performed, not by which parent company signs the paycheck. A Canadian sub claims SR&ED on its Canadian-performed work; a US entity claims Section 41 on its US-performed work. What you cannot do is claim the same dollar of expenditure under both systems — that’s not a grey area, it’s simply not how either program’s eligible-expenditure definition works. Clean intercompany documentation and a consistent transfer-pricing approach are what keep both claims defensible under audit.

Three Founders, Three Structures: Real Numbers

To make this concrete, consider three hypothetical but realistic scenarios, each spending roughly $1 million a year on qualifying R&D wages.

The bootstrapped Toronto CCPC. Pre-revenue, five engineers, fully Canadian-owned. At the 35% enhanced rate, this company can expect up to $350,000 back as a cash refund, arriving faster than ever under the new 90-day pre-claim process. That’s close to five months of payroll, delivered with no equity given up.

The Delaware C-corp with a Canadian dev team. Post-flip, non-CCPC status, same $1 million in Canadian engineering spend. The SR&ED claim now sits at the basic 15%, non-refundable — roughly $150,000 in future tax offset, not current cash. Meanwhile, if any US-based sales or product staff generate QREs domestically, those can separately access the QSB payroll offset up to $500,000, but only against actual US payroll tax and only while under the $5 million/five-year thresholds.

The pure US startup, QSB-qualified. All engineering onshore in the US, gross receipts under $5 million, founded within the last five years. Immediate deduction of the full $1 million under Section 174A, plus an ASC credit that — depending on QRE history — could reach the $500,000 payroll offset ceiling, applied dollar-for-dollar against quarterly payroll tax filings.

Same spend, three very different cash outcomes — and none of them is universally “correct.” They’re correct for the structure and stage they describe.

Common Mistakes That Cost Founders Real Money

Filing SR&ED late. The 18-month deadline after fiscal year-end is hard; miss it and the claim is gone permanently, no exceptions.
Assuming software isn’t eligible R&D. Both programs regularly approve software work — architecture redesigns, novel algorithms, systematic technical experimentation — founders just don’t file because they assume it’s “for scientists.”
Flipping to Delaware without modeling the SR&ED hit. Covered above, and still the most expensive surprise in this entire comparison.
Missing the QSB payroll offset window. Founders who are profitable-adjacent sometimes forget to elect the payroll offset before they cross the $5 million gross receipts line, leaving cash on the table permanently.
Double-claiming cross-border wages. Sloppy intercompany allocation between a US and Canadian entity is one of the fastest ways to trigger an audit on both sides of the border.
Not documenting technical uncertainty in real time. Both CRA and IRS reviewers want contemporaneous evidence of what problem you were solving and why the answer wasn’t obvious — retroactively reconstructed narratives are weaker evidence and slower to process.

Frequently Asked Questions

Can a US company claim SR&ED?

No. SR&ED is specific to research carried out by a Canadian taxpayer, generally performed in Canada (with the limited 10% foreign-wage allowance noted above). A wholly US-based company with no Canadian entity has no path into the program.

Can a Canadian company claim the US R&D tax credit?

Only for research activity actually conducted within the United States, through a US entity or a US branch generating US-source QREs. Work performed by Canadian-resident engineers in Canada doesn’t qualify as a US QRE, even if the parent company is US-incorporated.

Is SR&ED still worth it if my company isn’t a CCPC?

Yes, but at the reduced 15% non-refundable rate rather than the 35% refundable rate. It’s still real value, just deferred rather than immediate cash.

Does the US R&D credit still make sense now that Section 174A restored expensing?

Yes — they’re two separate benefits stacked on top of each other. Section 174A determines when you can deduct the expense; Section 41 is a separate credit calculated on top of that same spending. A qualifying company can claim both.

What’s the single biggest factor in the SR&ED vs R&D Tax Credit decision?

Refundability relative to your current profitability. If you’re pre-revenue, cash-in-hand from SR&ED almost always outweighs a higher headline percentage on a non-refundable US credit you can’t use yet.

The Bottom Line

SR&ED vs R&D Tax Credit isn’t a contest with one permanent winner — it’s a decision that should be revisited every time your company changes stage, raises a round, or moves engineers across the border. Canada still offers the strongest cash-in-hand benefit for pre-revenue, Canadian-controlled companies, especially after the 2026 expansion. The US has genuinely closed part of the gap with Section 174A’s return to immediate expensing and the $500,000 QSB payroll offset — but only for companies that fit inside specific size and age thresholds, and only for research performed on US soil.

The founders who get this right don’t pick a side once and forget about it. They model both programs against their actual cap table, their actual engineering headcount by country, and their actual fundraising timeline — ideally before a term sheet forces the decision for them. Talk to a cross-border tax advisor who has filed both an SR&ED claim and a Form 6765 in the same fiscal year. That combination of experience is rarer than it should be, and it’s exactly what this decision requires.

SR&ED vs R&D Tax Credit: 7 Brutal Truths for Founders (2026)

Must read